Novartis new CAR-T leukemia drug likely to be the most expensive ever – The Pharma Letter (registration)
The Pharma Letter (registration) |
Novartis new CAR–T leukemia drug likely to be the most expensive ever
The Pharma Letter (registration) The agency is also considering a CAR T-cell therapy from Kite Pharma. A third company, Juno Therapeutics, halted the development of one its CAR T-cell therapies after five patients died from complications of the treatment. CTL019 belongs to a new class … |
